Impetigo herpetiformis responsive to secukinumab.

Area of Science:

• Dermatology
• Immunology
• Obstetrics

Background:

• Pustular psoriasis during pregnancy presents significant management challenges.
• Limited therapeutic options exist for pregnant patients with severe skin conditions.
• Systemic immunosuppressants like steroids and cyclosporine may have safety concerns in pregnancy.

Observation:

• A pregnant patient with pustular psoriasis showed an unsatisfactory response to conventional treatments.
• Oral steroids and cyclosporine were administered but did not achieve adequate disease control.
• The patient's condition remained severe despite initial therapeutic interventions.

Findings:

• Secukinumab, a targeted interleukin-17A inhibitor, was administered to the patient.
• The patient experienced a significant improvement in pustular psoriasis symptoms following secukinumab treatment.
• This suggests secukinumab may be a viable option for managing pustular psoriasis in pregnancy.

Implications:

• Secukinumab offers a potential novel therapeutic avenue for pustular psoriasis in pregnant individuals.
• Further research is warranted to evaluate the safety and efficacy of biologics in pregnant dermatological conditions.
• This case highlights the need for tailored treatment strategies in managing complex dermatoses during gestation.